0001209191-18-057556.txt : 20181107 0001209191-18-057556.hdr.sgml : 20181107 20181107160906 ACCESSION NUMBER: 0001209191-18-057556 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181105 FILED AS OF DATE: 20181107 DATE AS OF CHANGE: 20181107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Biller Scott CENTRAL INDEX KEY: 0001581956 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 181166383 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 38 SIDNEY STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-05 0 0001439222 AGIOS PHARMACEUTICALS INC AGIO 0001581956 Biller Scott C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Scientific Officer Common stock 2018-11-05 4 M 0 3000 9.05 A 53932 D Common stock 2018-11-05 4 S 0 2200 69.44 D 51732 D Common stock 2018-11-05 4 S 0 700 70.23 D 51032 D Common stock 2018-11-05 4 S 0 100 71.42 D 50932 D Common Stock 6264 I See footnote Stock options (right to buy) 9.05 2018-11-05 4 M 0 3000 0.00 D 2023-04-30 Common stock 3000 4154 D This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.97 to $69.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.00 to $70.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee. This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. /s/ William Cook, as Attorney-in-fact for Scott Biller 2018-11-07